MediWound Valuation Multiples

MediWound Overview

About MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Founded

2000

HQ

Employees

111

Website

mediwound.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $19M

EBITDA: ($24M)

EV

$183M

Valuation Multiples

Multiples.vc

Start free trial

MediWound Financials

MediWound reported last 12-month revenue of $19M and negative EBITDA of ($24M).

In the same LTM period, MediWound generated $5M in gross profit, ($24M) in EBITDA losses, and had net loss of ($27M).

MediWound P&L

In the most recent fiscal year, MediWound reported revenue of $17M and EBITDA of ($20M).

MediWound expects next 12-month revenue of XXX and NTM EBITDA of XXX

MediWound Stock Performance

MediWound has current market cap of $228M, and enterprise value of $183M.

MediWound's stock price is $17.77.

MediWound Valuation Multiples

MediWound trades at 9.6x EV/Revenue multiple, and (7.7x) EV/EBITDA.

MediWound Financial Valuation Multiples

As of April 11, 2026, MediWound has market cap of $228M and EV of $183M.

Equity research analysts estimate MediWound's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

MediWound has a P/E ratio of (8.5x).

MediWound Margins & Growth Rates

MediWound's revenue in the last 12 month grew by 42%.

MediWound's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

MediWound's rule of 40 is (90%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

MediWound's rule of X is (21%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

MediWound Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

MediWound M&A Activity

MediWound acquired XXX companies to date.

Last acquisition by MediWound was on XXXXXXXX, XXXXX. MediWound acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

MediWound Investment Activity

MediWound invested in XXX companies to date.

MediWound made its latest investment on XXXXXXXX, XXXXX. MediWound invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).